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Post-translational modiﬁcationReversible tyrosine phosphorylation of proteins is a key regulatory mechanism to steer normal develop-
ment and physiological functioning of multicellular organisms. Phosphotyrosine dephosphorylation is
exerted by members of the super-family of protein tyrosine phosphatase (PTP) enzymes and many play
such essential roles that a wide variety of hereditary disorders and disease susceptibilities in man are
caused by PTP alleles. More than two decades of PTP research has resulted in a collection of PTP genetic var-
iants with corresponding consequences at the molecular, cellular and physiological level. Here we present a
comprehensive overview of these PTP gene variants that have been linked to disease states in man. Al-
though the ﬁndings have direct bearing for disease diagnostics and for research on disease etiology, more
work is necessary to translate this into therapies that alleviate the burden of these hereditary disorders
and disease susceptibilities in man.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
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tein kinase and protein phosphatase enzyme families. Phosphoryla-
tion of tyrosine residues within proteins in order to steer cell
decisions rapidly took center stage in the period that multicellularity
evolved [1] and, accordingly, mutations in protein tyrosine kinase
genes and the signaling pathways they control underlie growth de-
fects and developmental disorders in man (e.g. [2]). It is therefore
to be expected that enzymes of the super-family of protein tyrosine
phosphatases (PTPs) are equally important to safeguard physiological
processes, and indeed PTP gene inactivation studies in model organ-
isms revealed developmental abnormalities for several representa-
tives [3,4]. Some twenty-ﬁve years ago the ﬁrst PTP sequences were
unraveled, and the current list holds over a hundred distinct PTP
genes within the human genome [5]. Research since then not only
ﬁrmly established their diverse roles in multicellular signaling path-
ways but also convincingly demonstrated PTP involvement in various
human disorders and disease susceptibilities [4,5]. Mutations and ex-
pression alterations of PTP genes that occur in human somatic cells
have been reviewed extensively over the past years [6–10]. Here,
we present a comprehensive overview of the current knowledge on
PTPs that are implicated in hereditary human pathologies (Fig. 1).
Main characteristics are compiled in Table 1.
We will ﬁrst discuss class I cysteine-based non-transmembrane and
receptor-type PTP genes of the ‘classical’ phosphotyrosine-speciﬁc en-
zyme subfamily, before embarking on genes encoding so-called dual
speciﬁcity phosphatases (DUSPs). DUSP-type PTPs not only remove
phosphate groups from phospho-tyrosines but many also catalyze the
dephosphorylation of phospho-threonine and phospho-serine residues.
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Fig. 1. PTP gene family members that link to human disease predisposition. Shown are human gene names (on a pink background) and representative schematic domain depictions for
PTPs that have been associated with hereditary disorders or disease susceptibilities. Themain PTP classes and their subdivisions (yellow and orange background, respectively) according
to Alonso et al. [11], with inclusion of the TULA family [19] as a ﬁfth class, are indicated. Note that CDC14 and slingshot type DUSP subfamilies (containing 4 and 3 genes, respectively) are
not included because as yet no link to a hereditable human disease state has been described. Numbers between brackets reﬂect the number of disease-linked genes versus the total num-
ber of genes in that particular PTP (sub)class. The panel on the right provides a legend to the protein domains used in the schematic depictions of the PTPs in each subclass. The black
double line that comes with the receptor-type PTP drawings symbolizes the cell membrane. Note that PTP catalytic domains are in pink and on the cytosolic side. Drawings are to
scale and a size indication is included. See the text sections on the respective PTPs for detailed description and references.
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hydrates or oligonucleotides as substrates [11,12]. In the end we will
discuss two out of the four aspartate-based ‘Eyes Absent’ PTP genes,
which encode enzymes that use an aspartic acid residue instead of the
usual cysteine at their catalytic center.
For many of the PTP disease genes either loss-of-function or gain-
of-function mutations have been documented, but for other PTPs thus
far single nucleotide polymorphisms (SNPs) have been associated with
disease susceptibilities and mechanistic links remain to be elucidated
(Fig. 2). A depiction of putative mechanisms that connect some of the
addressed PTPs with hereditary human disorders or disease susceptibili-
ties is provided in Fig. 3. To our knowledge, no evidence exists yet on
the involvement of the class III cysteine-based CDC25 PTPs in hereditary
humandisease, with the exception of the report of single nucleotide poly-
morphisms (SNPs) at the CDC25A gene which confer a risk to develop
breast cancer [13]. Also for the highly polymorphic gene ACP1, encoding
the class II cysteine-based LMW-PTP “red cell acid phosphatase”, allelic
variants have been reported to associatewith a variety of humandiseases,
including diabetes, allergic and autoimmune inﬂammatory disorders, id-
iopathic epilepsies, cancer, and vascular disease [14–18]. About a decade
ago a ﬁfth PTP class, characterized by a histidine as the essential residue
in their active site, could be added to the superfamily (Fig. 1). The twodis-
tinct genes, UBASH3A and UBASH3B, encode TULA-family proteins that
down-regulate receptor-mediated signals in T-cells and platelets [19],
and non-coding SNPs within the genes showed linkage to autoimmune
disease susceptibility (Fig. 4). These association studies prompt for further
experiments to disclose whether and how the class II, III and V PTPs may
inﬂuence the involved pathologies.2. Cys-based classical, non-transmembrane PTPs
2.1. PTPN1
The gene PTPN1, encoding the paradigm protein tyrosine phos-
phatase PTP1B that resides at the endoplasmic reticulum, is located
in a genome region (20q13.1–q13.2) that represents a susceptibility
locus for the development of insulin resistance in type 2 diabetes
mellitus [20]. This region spans some 20-odd genes, several of
which have ties with insulin signaling and energy metabolism, and
evidence was provided for a direct role of PTP1B [21–26]. This is in
line with the ﬁnding that PTP1B dephosphorylates, hence inactivates,
the insulin receptor and several downstream targets [27]. In the 3′
untranslated region of the PTPN1messenger a single nucleotide inser-
tion was observed that was associated with features of insulin resis-
tance in two different populations. Importantly, this insertion led to
higher PTPN1 transcript levels in skeletal muscle due to an increase
in mRNA stability as compared to the wild-type transcript. Thus, the
1484insG allele causes PTP1B overexpression and contributes to the
development of insulin resistance [21]. This is consistent with the
ﬁndings that PTP1B knockout mice exhibit increased sensitivity to in-
sulin and are resistant to high-fat diet-induced diabetes and obesity
[28,29], and that decrease of miRNA-122, which targets PTP1B
mRNA, causes hepatic insulin resistance in mice [30]. Moreover, anti-
sense oligonucleotides targeting PTP1B improve insulin sensitivity in
rodent and monkey models [31,32], indicating that reducing PTP1B
levels could be an appropriate therapy for type 2 diabetes in humans
(see below).
Table 1
Properties of PTPs involved in hereditary human disorders and/or disease susceptibilities.a
Gene
(Chrom.loc)
Protein
Phenotype in knock-out mouse models Hereditary human disorder/disease
susceptibility
Mutation type—effect in disease
Cys-based classical PTPs, non-receptor
PTPN1
(20q13.1–13.2)
PTP1B
Increased insulin sensitivity
Resistance to obesity
Type 2 Diabetes Mellitus (T2DM)
Hypertension & related metabolic traits
(e.g. cholesterol levels)
3′UTR SNP—increased mRNA
stability
SNPs—hyperalleles?
SNPs (incl. p.P387L)—?
PTPN2
(18p11.3–11.2)
TCPTP
Growth retardation, thymic atrophy, defective
haematopoiesis and immune function, systemic
inﬂammation, postpartum lethality
Inﬂammatory Bowel Disease (incl.
Ulcerative Colitis, Crohn's disease)
Rheumatoid Arthritis, Type 1 Diabetes
Mellitus (T1DM)
Upstream SNP—Decreased?
Intronic SNP—Decreased
PTPN5
(11p15.1)
STEP
Enhanced ERK1/2 phosphorylation in relevant
brain areas, improved cognitive performance,
reduced amnesic effects of alcohol
Schizophrenia/Cognition disorders SNPs—Increased transcript levels
PTPN6
(12p12–13)
SHP1
me, mev: chronic inﬂammation, autoimmunity
meB2: autoinﬂammation similar to neutrophilic
dermatoses
Neutrophilic Dermatoses SNP (p.E441G) & Del—reduced activity
PTPN7
(1q32.1)
HePTP
Enhanced ERK1/2 phosphorylation in T cells Height in infants SNP—?
PTPN11
(12q24)
SHP2
Early embryonic lethal, survival signaling defects Noonan Syndrome
Leopard Syndrome
Juvenile Myelomonocytic Leukemia
Metachondromatosis
Tetralogy of Fallot, T1DM, Systemic
Lupus Erythematosus (SLE)
Gain-of-function
Loss-of-function
Gain-of-function
Loss-of-function
Intronic SNP—?
PTPN12
(7q11.23)
PTP-PEST
Embryonic lethal Risk for breast cancer SNP—reduced activity
PTPN13
(4q21.3)
PTPN13
Reduced nerve repair
Improved host defense against intrapulmonary K.
pneumoniae
Familial hepatocellular carcinoma
Risk for NHSCC, lung carcinoma, and co-
lorectal cancer
SNP—reduced activity
SNPs—altered activity
PTPN14
(1q32.2)
Pez
Limb swelling
Periorbital edema
Lymphatic capillary hyperplasia
Congenital Lymphedema
Haemorrhagic Telangiectasia
Del—Loss-of-function
SNP—?
PTPN21
(14q31.3)
PTPD1
No reports Schizophrenia SNPs (p.V936A, p.L385F)—?
PTPN22
(1p13.2)
Lyp
Effector/memory T-cell expansion resulting in
splenomegaly and lymphadenopathy upon ageing
Altered regulatory T cell levels in thymus
T1DM, Rheumatoid Arthritis, Hashimoto
Thyroiditis, Graves Thyroiditis, SLE,
Familial Hypoadrenocorticism/Addison's
Disease, Psoriasis, ANCA
Systemic Lupus Erythematosus
SNP—p.R620W risk allele
SNP—p.R263Q protective effect
Cys-based classical PTPs, receptor
PTPRA
(20p13)
RPTPα
Neurodevelopmental and peripheral myelination
defects
Impairments in synaptic plasticity and short-term
memory
Schizophrenia Intronic SNP—Altered isoform ratio?
PTPRC
(1q31–q32)
CD45
No T cells, impaired positive and negative selection
of B-cells
Myelination defects
Severe Combined Immunodeﬁciency
Multiple Sclerosis
Hepatitis C Virus Susceptibility
Rheumatoid Arthritis
Loss-of-function
77G SNP—isoform switch, increased
activity
77C SNP—isoform switch, reduced
activity
SNP—?
PTPRD
(9p24.3–p23) RPTPδ
Growth retardation, posture and motor defects,
impaired learning and memory, early mortality
Restless Legs Syndrome
Clear cell Renal Cancer
5′UTR SNPs—RNA production/
stability ?
5′UTR SNP—Reduced expression
PTPRF
(1p34)
LAR
Defects on mammary gland development and milk
production
Decreased size and number of basal forebrain
cholinergic neurons
Spatial learning impairment
Syndromic amastia
T2DM and related coronary artery
disease
Translocation—Protein absence
Intronic SNP—?
PTPRJ
(11p11.2)
DEP-1
SFK-mediated regulatory function in B cells and
macrophages
Platelet phenotype: bleeding tendency, defective
arterial thrombosis
Early-onset Familial Colorectal Cancer
Risk for breast cancer, papillary thyroid
carcinoma, head and neck squamous cell
carcinoma, lung carcinoma
Heparin-induced thrombocytopenia
Micro-duplication—Epigenetic
silencing
SNPs—?
SNPs—Loss-of-function?
PTPRN2
(7q36)
Phogrin
Reduced glucose-stimulated insulin release Co-morbid Cocaine Dependence and
Major Depressive Episode
Attention Deﬁcit Hyperactivity Disorder
SNP—?
CNV—?
PTPRO
(12p12.3)
GLEPP1
Podocyte abnormalities, hypertension, reduced
glomerular ﬁltration
Abnormal DRG development, perturbed
nociception and proprioception
Idiopathic Nephrotic Syndrome
Neurocognitive diseases
Splice mutant—loss of function
Intronic SNPs—?
(continued on next page)
1675W.J.A.J. Hendriks, R. Pulido / Biochimica et Biophysica Acta 1832 (2013) 1673–1696
Table 1 (continued)
Gene
(Chrom.loc)
Protein
Phenotype in knock-out mouse models Hereditary human disorder/disease
susceptibility
Mutation type—effect in disease
PTPRQ
(12q21.2)
PTPRQ
Auditory hair bundle defects, defective vestibular
hair cells
Autosomal Recessive Nonsyndromic
Hearing Loss 84 (DFNB84)
Loss-of-function
PTPRR
(12q15)
PCPTP1
Elevated MAPK phospho-levels in speciﬁc brain
areas, impaired locomotion and balancing skills
Major Depressive Disorder intronic SNP—gain-of-function?
PTPRS
(19p13.3)
RPTPσ
Reduced brain size, abnormalities in pituitary and
olfactory lobes
Improved nerve regeneration
Altered glucose homeostasis, Ulcerative colitis
T2DM
Ulcerative Colitis
SNPs—?
intronic SNPs—inﬂuence splicing
(exon skipping)
PTPRZ1
(7q31.3)
RPTPζ
Defects in remyelination
Learning impairment
Decreased B-cell survival
Schizophrenia SNPs—increased expression
Cys-based DUSP PTPs
DUSP1
(5q34)
MKP1
Enhanced innate immunity
Inﬂammatory bone loss
Sensitivity to collagen II-induced arthritis
Exacerbation of colitis in IL-10 deﬁcient mice
Increased acetaminophen-induced hepatic injury
Defective skeletal muscle regeneration
Resistance to diet-induced obesity
Protection against atherosclerosis in ApoE-null
mice
Clinical response to inhaled
corticosteroid therapy in asthma patients
SNPs—increased levels?
DUSP6
(12q22–23)
MKP3
Dwarﬁsm-related skeletal abnormalities and
deafness
Cardiac hypercellularity
Bipolar Disorder SNPs (p.L114V, p.S144A)—hyperactivity?
PTEN
(10q23.3)
PTEN
PTEN null mice: embryonic death at day 8
Heterozygous mice: highly susceptible to tumor
formation
PTEN Hamartoma Tumor Syndrome
Macrocephaly/Autism Syndrome
Atherosclerotic cerebral infarction
Chronic obstructive pulmonary disease
Loss-of-function mutations
Loss-of-function mutations
SNPs—?
SNPs—?
PTP4A1
(6q12)
PRL-1
No reports Alcohol Dependence SNPs—?
MTM1 (Xq28)
MTM1
Muscle atrophy, respiratory disfunction, die within
2 months
X-linked Myotubular Myopathy Loss-of-function mutations
MTMR2
(11q22)
MTMR2
myelin outfoldings, speciﬁcally in Schwann cells,
impaired nerve conduction
Charcot–Marie–Tooth disease 4B1 Loss-of-function mutations
MTMR3
(22q12.2)
MTMR3
No reports Susceptibility to lung and gastric cancer,
and to childhood onset inﬂammatory
bowel disease
SNPs—decreased mRNA levels?
MTMR7
(8p22)
MTMR7
No reports Risk to variant Creutzfeldt-Jakob SNP—?
MTMR9
(8p23-p22)
MTMR9
No reports Susceptibility to metabolic syndrome
and obesity
SNP—?
SBF2
(11p15.4)
MTMR13
nerve conduction defects and abnormal myelin
folding
Charcot-Marie-Tooth disease 4B2
Stature
Loss-of-function mutations
SNP—?
MTMR14
(3p25.3)
MTMR14
skeletal muscle phenotype: fatigue, reduced
tolerance to exercise, abnormal T-tubule morphol-
ogy, increased autophagy
Autosomal Centronuclear Myopathy Loss-of-function mutations
EPM2A
(6q24)
Laforin
Neuronal degeneration, Lafora inclusion body
formation resulting in impaired behavioral
responses, ataxia and seizures
Myoclonic Epilepsy of Lafora Loss-of-function mutations
Asp-based PTPs
EYA1
(8q13.3)
EYA1
Defects in development of multiple organs,
respiratory failure at birth
Branchio-Oto-Renal Syndrome 1
Oto-facio-cervical Syndrome
Vesico-ureteral reﬂux
Loss-of-function mutations
Large deletions (ﬂanking genes)
SNP—trend only
EYA4
(6q23)
EYA4
Defects in eustachian tube and middle ear Autosomal Dominant Deafness 10
Dilated Cardiomyopathy
Holoprosencephaly
Anti-TNF therapy responsiveness in RA
Loss-of-function
Additional Loss-of-function
Large deletion
Intronic SNP—?
?: The effect of the SNP on PTP transcript levels or protein activities is currently unknown.
a See the text sections on the respective PTPs for detailed description and references.
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increased risk for type 2 diabetes in the Danish Caucasian population
[23]. Thismutation hampers the phosphorylation of a nearby conservedserine residue in PTP1B but it remains to be demonstrated whether the
unphosphorylated variant has a higher enzymatic activity. In a local
subarctic community in central Canada a SNP in PTPN1 exon 8 was
Mutations linked to disease
SNPs associated with disease susceptibility
non-proteinaceous
unknown
proteinaceous
loss of function
unknown
gain of function
Effect of mutation/
Effect of SNP:
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Fig. 2. Venn diagram showing the distribution of PTP gene variantswith respect to disease-causingmutations (reddish purple square) or modiﬁers of disease susceptibility (green square
on the left). Gene name colors symbolize the mutation's effect on enzyme activity, and vertical segmentation by the dashed lines reﬂects the substrate preference of the PTPs involved, as
indicated in the rightmost (grey) panel. Asterisk indicates a myotubularin-type PTP that lacks enzymatic activity. See the text sections on the respective PTPs for detailed description and
references.
1677W.J.A.J. Hendriks, R. Pulido / Biochimica et Biophysica Acta 1832 (2013) 1673–1696found associated with reduced risk for either impaired glucose toler-
ance or type 2 diabetes [22]. This SNP is silent at the amino acid level,
however, and therefore does not add to mechanistically deﬁning a pro-
tective role for PTP1B. Bowden and coworkers used a comprehensive
set of SNPs covering the PTPN1 genomic region and found that all
SNPs within the PTPN1 transcription unit signiﬁcantly associated with
type 2 diabetes, insulin sensitivity and fasting glucose levels but only
two (including 1484insG) did so with acute insulin responsiveness in
the Caucasian population [24,26]. It is tempting to speculate that the
non-coding SNPs have bearing for the corresponding PTPN1 transcript
levels in insulin-responsive tissues, but this awaits assessment. ForMood disorders
ERK1/2
hypoactivation 
Defective 
myelination
Glu-receptor
internalization
Secretory 
vesicle release
Cancer predisposition
Proliferation, transformation, pro-survival
Fyn
Src
STAT3
Ras
ERK
SFKs,
RTKs AURKA PI(3,4,5)P3
SFKs,
RTKs
DUSP6
PTPRR
PTPN21 PTPRA PTPRZ1PTPN5PTPRN2
PTPN13PTPN11 PTPRJ PTENPTPRD
Fig. 3. Possible mechanisms involving selected PTPs in human hereditary mood disorders (top
betesmellitus (lower right). Themechanistic insights usually are based on a combination of phe
ing from patient data, and functional tests at the molecular level in appropriate cell models. Col
unknown. Arrows, positive effect; blunted arrows, negative effect; dotted arrows, indirect effereasons of completeness, it should be noted that the associations of
PTPN1 SNPs with type 2 diabetes could not be replicated in some co-
horts (e.g. [33,34]).
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region a contribution of PTP1B to the pathogenesis of hypertension,
i.e. dyslipidemia and obesity, was noted in Chinese subjects [35].
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Fig. 4. PTP hereditary disease genes grouped according to their local (top) or more systemic (bottom) phenotypic effects. See the text sections on the respective PTPs for detailed
description and references. Asterisk; note that dermatoses related to PTPN6 variants reﬂect an inﬂammatory disease due to neutrophil dysfunction.
1678 W.J.A.J. Hendriks, R. Pulido / Biochimica et Biophysica Acta 1832 (2013) 1673–1696in PTPN1 intron 6was also shown to impact on body fat distribution and
type 2 diabetes risk [25]. In that study [25] also the association of the
PTPN1 P387L mutation with lower glucose tolerance was conﬁrmed.
Taken together, although type 2 diabetes and obesity are clearly
multifactorial diseases and PTP1B protein activity studies in patient
samples are lacking, the mounting evidence that PTP1B activity is a de-
termining factor in these diseases warrants the further quest for phar-
macologically effective inhibitors to conquer these major disease
states (Figs. 3–4).
2.2. PTPN2
PTPN2 is closely related to PTPN1 and encodes TCPTP, an intracellu-
lar PTP that comes in two ﬂavors: a cytosolic variant and a nuclear
splice-isoform [38,39]. The detection of PTPN2 focal deletions in a subset
of human T-cell acute lymphoblastic leukemias illustrated its tumor
suppressive effect in lymphoid cells [40]. PTPN2 role in immune regula-
tion is reﬂected by its identiﬁcation as a susceptibility locus for autoim-
mune diseases, including Crohn's disease (CD), rheumatoid arthritis
(RA) and type 1 diabetes [20,41]. This is substantiated by multiple re-
cent ﬁndings, including a conﬁrmatory study under Spanish subjects
[42]. Genetic association studies in large cohorts of inﬂammatory
bowel disease patients has ultimately, by means of a meta-analysis of
data frommultiple independent studies, provided a signiﬁcant associa-
tion with a SNP at the PTPN2 locus, some 5 kbp upstream of the tran-
scription unit [43,44]. Inﬂammatory bowel disease represents a
genetically heterogeneous collection of pathologies, including CD and
ulcerative colitis. Furtherwork should unravel which of the PTPN2 char-
acteristics are altered in the SNP-associated allele as compared to wild
type but, in view of the impact of the associated protein on immune
cell signaling [45], this points into the direction of reduced levels and
functionality. Indeed, TCPTP deﬁciency in mice results in reduced
growth and systemic inﬂammation, culminating in lethality around
one month of age. Importantly, these effects on myeloid and bonedevelopment and on overall survival are greatly inﬂuenced by the ge-
netic background of the mice [46].
As of the molecular mechanism, a recent study revealed that a
disease-associated, intronic variant of PTPN2 led to decreased TCPTP ex-
pression (as compared to the normal allele) in T cells, and negatively im-
pacted on the IL-2 and IL-15 responsiveness of these cells [47]. The
authors speculate that reduced TCPTP levels indirectly lead to enhanced
activity of potential inhibitors of IL-2Rβ signaling, thereby regulating cyto-
kine responsiveness and autoimmune susceptibility. Studies in mice re-
vealed that TCPTP-deﬁcient CD8+ T cells alone are sufﬁcient to transfer
inﬂammation and autoimmunity to wild-type recipient animals [48].
Subsequent experiments demonstrated that, by dephosphorylating and
inactivating Src family kinases (SFKs), TCPTP normally blunts antigen-
induced T cell activation and proliferation [48], indicating that PTPN2 dis-
ease alleles thus cause a lowering of in vivo thresholds for TCR-dependent
responses.
But TCPTP's relevance for chronic inﬂammatory disorders may well
extend beyond T cell functioning, as put forward by recent work on
human intestinal cells that were obtained from CD patients or healthy
controls [49]. Earlier work had shown that the autophagy gene
ATG16L1 is associated with chronic inﬂammatory disorders, and this
prompted the investigators to monitor presence of CD-associated
PTPN2 or ATG16L1 variants and the process of autophagosome forma-
tion in the specimens. Collectively, their results now suggest a model
in which cytokines—in an mTOR/ATG16L1-dependent way—induce
TCPTP activity in the intestinal cells, thereby triggering a negative feed-
back loop on EGFR-mediated mTOR activity and promoting autophagy.
Reduced TCPTP levels thus boost mTOR activation and impair autopha-
gy, which leads to increased infection burden and elevated apoptosis of
intestinal epithelial cells [49].
PTPN1 and PTPN2 are two highly related genes, coding for proteins
with an amino acid identity of 73% at their PTP domain. This makes a
speciﬁc interference with the catalytic activity of PTP1B or TCPTP,
which could be beneﬁcial in therapies against type 2 diabetes and
1679W.J.A.J. Hendriks, R. Pulido / Biochimica et Biophysica Acta 1832 (2013) 1673–1696obesity (PTP1B inhibition-based therapy) or against inﬂammatory
diseases (TCPTP activation-based therapy), extremely challenging.
Alternative mechanisms to interfere with PTP1B or TCPTP function-
ing, including speciﬁc regulation of protein levels, subcellular loca-
tion, or targeting to substrates, need to be considered.
2.3. PTPN5
The brain-speciﬁc phosphatase termed STEP (Striatal-enriched pro-
tein tyrosine phosphatase) is encoded by gene PTPN5 and regulates syn-
aptic plasticity and neuronal function in the central nervous system
through dephosphorylation of key target molecules including MAP
kinases, SFKs and NMDA and AMPA receptor subunits [50]. STEP-
mediated dephosphorylation inactivates the SFK targets but for the
NMDA and AMPA receptor complexes this triggers their endocytosis.
Ptpn5 knock-out mice have a normal brain morphology but increased
levels of MAP kinase phosphorylation in speciﬁc brain areas, improved
hippocampal-dependent learning andmemory, and amore dominant be-
haviorwere noted [51,52]. Evidence is accumulating that dysregulation of
STEP also contributes to the pathophysiology of several neuropsychiatric
disorders in man [53]. Schizophrenia affects 1% of the world population
and is characterized by altered synaptic transmission, a decrease in
white matter, and hypomyelination [54,55]. The disease is highly herita-
ble, and the list of candidate genes that display linkage includes multiple
genes important formyelination and oligodendrocyte development. A ge-
netic association of PTPN5with schizophrenia and cognitive performance
was recently discovered in a Jewish population using SNP haplotypes that
reside within the PTPN5 gene [56]. Moreover, preliminary data suggest
that these disease-associated alleles result in higher STEP transcript levels
[56]. Combined with previous ﬁndings that glutamate receptor internali-
zation contributes to the pathogenesis of schizophrenia, that elevated
STEP levels are found in the prefrontal cortex of Alzheimer's patients,
and that reduction of STEP levels inmice improves cognitive performance
[53], this yields the picture that aberrancies in STEP activity levels contrib-
ute to neuropathologies. STEP-speciﬁc inhibitors that are able to pass the
blood–brain-barrier would therefore be appealing drugs to treat a subset
of psychiatric disorders and related cognitive defects.
2.4. PTPN6
Genes PTPN6 and PTPN11 both encode tyrosine-speciﬁc phospha-
tases that harbor tandem N-terminal Src homology type 2 (SH2) do-
mains. These PTPs exist in a closed, inactive conformation in which
the N-terminal SH2 domain prevents access to the catalytic domain. Ac-
tivation requires that this N-terminal SH2 domain starts binding
phospho-tyrosine residues in other proteins, thereby opening up the
catalytic domain in the PTP [57]. Naturally occurring mouse mutants
that suffer from complete or partial inactivation of the Ptpn6 gene, des-
ignated “motheaten” and “motheaten viable”, respectively, have pro-
vided insight into the biological function of the Ptpn6-encoded
protein, SHP1 [58]. The homozygous mutant mice suffer from chronic
inﬂammation and autoimmunity and their lifespan is considerably re-
duced. Heterozygous animals develop lymphoma and leukemia at
higher age. Collectively the data show that SHP1 functions as an impor-
tant regulator of the myelopoietic system [59]. Of course this is exerted
by dephosphorylating key substrates, which includemultiple RTKs [60].
Motheaten mice display focal skin inﬂammations and patchy ab-
sence of hair, due to increased numbers of neutrophils in the subder-
mal tissue [58]. Similar pathologies—i.e. extensive skin inﬁltration by
neutrophils—are present in humans that suffer from pyoderma
gangrenosum and Sweet's syndrome, but the genetic causes of these
two uncommon neutrophilic dermatoses that are associated with he-
matological tumors are currently not known. It will therefore come as
no surprise that patients with idiopathic neutrophilic dermatoses
were recently investigated for potential PTPN6 abnormalities [61]. In
one patient indeed a combined heterozygous mutation (E441G) inthe SHP1 catalytic domain and a 1.7-kbp deletion that altered PTPN6
expression could account for disease development, but all other
cases revealed no mutations in PTPN6 gene sequences. Sharply con-
trasting with healthy control material, however, all these patient
samples displayed next to the full-length SHP1 mRNA an abundance
of PTPN6 splice variants that likely encode nonfunctional protein
[61]. Given that also SHP1 phosphatase activity was found reduced
in leukocytes of neutrophilic dermatoses patients, and that a sponta-
neous insertional mutation in mouse Ptpn6 renders a neutrophilic
dermatosis phenotype [62], it is warranted to conclude that reduced
SHP1 activity provides the molecular explanation of the pyoderma
gangrenosum and Sweet's syndrome phenotypes. In the majority of
cases, however, the disease genes involved will rather function in
PTPN6 transcript processing.
2.5. PTPN7
HePTP is a hematopoietic enzyme encoded by the PTPN7 gene and,
like PTPN5-encoded STEP, HePTP contains a so-called kinase interaction
motif that determines its binding to and dephosphorylation of MAP ki-
nases [63]. In doing so, HePTP could potentially block TCR-induced signal
transduction. However, Ptpn7 knock-out mice display no phenotypic
consequences whatsoever and only in vitro a mild enhancement of
MAPK activation following TCR stimulation was noted [64]. This points
to efﬁcient compensatory mechanisms in mouse and makes it hard to
explain how a SNP analysis in Vietnamese-Korean families could point
to human PTPN7 as a genetic factor associated with height during early
childhood [65]. Clearly, the proposed link is in need of replication in ad-
ditional cohorts.
2.6. PTPN11
PTPN11 encodes SHP2, a close homolog of SHP1 and also having two
SH2 domains. Many acquired and hereditary disease phenotypes are at-
tributable to this protein [66–69]. Intriguingly, since both PTPN11
loss-of-function and gain-of-function mutations are incompatible with
healthy life [70], this exempliﬁes how important exact ﬁne-tuning in re-
versible phospho-tyrosine-mediated signaling in fact is. Many receptor-
type molecules, including growth factor and cytokine receptors, act up-
stream of SHP2 and regulate the balance between its open (active) and
closed (inactive) conformation [71]. Once activated, its primary targets
reside in the Ras-ERK MAP kinase and Jak-STAT signaling pathways
[67]. SHP2 hyperactivity causes Noonan syndrome (NS), an autosomal
dominant dysmorphic syndrome that has an estimated incidence of 1
in 1000 to 2500 newborns [69]. It is characterized by hypertelorism,
downward eyeslant, low-set posteriorly rotated ears, and also short stat-
ure, webbed neck, cardiac anomalies, epicanthic folds, deafness, motor
delay and bleeding diathesis have been observed. Moreover, an in-
creased risk for hematological malignancies and other cancers has been
found for NS patients [72,73]. Decreased catalytic activity of SHP2, on
the contrary associateswith LEOPARD syndrome, a genetically heteroge-
nous disorder that manifests with multiple lentigines, cardiac conduc-
tion abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal
genitalia, retardation of growth, and sensorineural deafness. The partial
overlap in phenotypic consequences observed for these two syndromes
[66] suggests that SHP2 hypo- and hyper-activity affect developmental
pathways in a similar manner [70]. SHP2 NS mutations mainly disrupt
the inhibitory interaction between the N-terminal SH2 and the catalytic
domain; on the other hand, SHP2 LEOPARD syndromemutations mainly
reside in the catalytic domain, reducing catalytic activity but increasing
binding to upstream activators and scaffolding adapters [74,75].
Ras-ERK MAP kinase signaling is a key pathway downstream of mutant
SHP2 (Fig. 3) which is further substantiated by the discovery of activat-
ing mutations in other factors of the pathway in NS and LEOPARD
syndrome patients [69]. Moreover, the mutation spectrum that is
found in the juvenile myelomonocytic leukemia (JMML) and associated
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well as germline NRAS, KRAS2, NF1 and ARHGAP26mutations that result
in enhanced Ras-MAPK signaling [66–69]. The examples of mutational
overlapping between NS and JMML are rare, and it has been proposed
that isolated NS germline PTPN11 mutations have milder gain-of-
function phenotypes than mutations from isolated JMML and other
pediatric myelodisplastic disorders [74]. In addition, STAT3 function
downstreamof SHP2 is also involved inNS phenotype (Fig. 3). The hema-
topoietic phenotype of STAT3 deﬁcient mice shows high autonomous
myeloid cell proliferation which resembles the phenotype of mice
carrying a knock-in hyperactive SHP2 mutant [77]. SHP2-mediated de-
phosphorylation and inactivation of STAT3 thus contributes to the patho-
genesis of NS and JMLL [78].
Recently, a newMendelian diseasewas added to the PTPN11 track re-
cord. Next generation sequencing technology allowed the analysis of the
full genome of a single patient with the autosomal dominant incom-
pletely penetrant combined exostosis and enchondromatosis tumor syn-
drome termedmetachondromatosis [79]. A deletion in PTPN11 exon four
that co-segregated with the phenotype and that alters the SHP2 reading
frame causing a premature stop was found. The results could be con-
ﬁrmed in a second affected family that displayed a nonsense mutation
in PTPN11 exon 4 [79]. In an independent study, also classical linkage
analysis using SNP arrays and ultimately targeted sequence analysis led
to the identiﬁcation of PTPN11 loss-of-function mutations in about half
of the investigated metachondromatosis families [80]. Importantly, in
microdissected lesions from patients loss-of-heterozygosity for the
wild-type allele could be demonstrated, underscoring the tumor sup-
pressive nature of SHP2 activity in the affected cell types [80]. In the re-
lated multiple enchondromatosis disorders Ollier disease and Maffucci
syndrome no loss-of-function mutations in PTPN11 could be detected.
Lastly, an association study for common genetic variants of 22 can-
didate genes underlying tetralogy of Fallot, a congenital heart defect
that often presents in the context of multisystemic diseases like
Down syndrome and Holt-Oram syndrome, revealed a single SNP at
the PTPN11 locus in a British cohort [81]. Intriguingly, the PTPN11
SNP that was found associated with tetralogy of Fallot is in intron 6
and has also been linked with autoimmune disorders like type 1 dia-
betes and systemic lupus erythematosus (SLE). It is as yet unclear
whether it is causing altered PTPN11 expression or rather acts on
other, neighboring genes that are involved in T-cell signaling.
2.7. PTPN12
PTPN12 encodes PTP-PEST, a ubiquitous protein with abundance in
hemopoietic and epithelial cells that contains a long C-terminal domain
with several proline-rich and PEST motifs. In the immune system,
PTP-PEST negatively regulates TCR and BCR signaling [82]. By virtue of
its association to or dephosphorylation of adapter, signaling and cyto-
skeletal proteins, PTP-PEST is also a major regulator of cell adhesion,
motility and migration [83]. Both tumor suppressive and oncogenic
properties have been assigned to PTP-PEST in human breast cancer. A
tumor promoting mode of action was based on the ﬁnding that
PTP-PEST protected cells against aberrant ROS accumulation and oxida-
tive stress-induced death [84]. In support of the opposite scenario is the
ﬁnding that a T573A SNP in PTPN12, that resulted in a partial
loss-of-function variant when tested for capacity to suppress transfor-
mation in PTPN12-depleted cells, is enriched in breast cancer patients
as compared to healthy controls [85]. Oddly enough, the T573A variant
rather displayed increased phosphatase activity when tested in vitro
[86]. Additional studies may add up to a more decisive picture on the
role of PTP-PEST in breast cancer.
2.8. PTPN13
Gene PTPN13 resides at chromosome4q21.3 and it encodes the larg-
est human non-transmembrane PTP; it consists of a KIND (putativekinase non-catalytic C-lobe domain) domain, a FERM (acronym for
Band 4.1, Ezrin, Radixin, Moesin) domain and ﬁve PDZ (PSD95, Dlg,
ZO-1) domains in addition to its single, C-terminal catalytic PTP domain
[87]. This impressive and unique repertoire of anchoring and scaffolding
domains suggested an important role for PTPN13 in submembranous
signaling events but remarkably the phenotypes of Ptpn13 mutant
mice appeared extremely subtle [88,89]. The 4q region is often found
deleted in hepatocellular carcinomas and this prompted investigations
towards a possible involvement of PTPN13 in tumorigenesis. Multiple
reports on somatic PTPN13 mutations in cancer specimens penetrated
the literature [90,91] and, additionally, several PTPN13 polymorphic al-
leles were found to increase the risk of developing multiplex familial
hepatocellular carcinoma [92], head and neck squamous cell carcinoma
[93], or lung and colorectal cancer [94]. A few suchpolymorphic PTPN13
variants have been investigated at the protein level and were found to
reduce the binding capacity of PTPN13's second PDZ domain [92], ap-
parently contrasting with the effects of somatic PTPN13 mutations in
cancer specimens that rather result in the loss of catalytic PTP activity
[95,96]. The advent of next generation sequencing techniques will un-
doubtedly further ﬁll the catalog of disease-related PTPN13 variants,
and it will be insightful to document whether these impinge on the
protein's interaction domains or rather its catalytic C-terminal end.2.9. PTPN14
The PTPN14-encoded protein Pez also combines a membrane-
associating FERM domain with a PTP catalytic segment but as compared
to PTPN13 it lacks KINDandPDZdomains. In a consanguineous Yemenite
family, a homozygous 2 kbp deletion within the PTPN14 gene has been
found in affected individuals with autosomal-recessive lymphedema-
choanal atresia syndrome [97]. The concomitant loss of PTPN14 exon 7
causes a frameshift, resulting in a prematurely truncated, instable Pez
protein that spans until halfway its FERM domain and lacks catalytic ac-
tivity. To substantiate the ﬁndings a gene-trap mouse model was gener-
ated that indeed partially recapitulated the disease phenotype [97].
Although animals did not develop choanal atresia, a considerable num-
ber had swelling of the limbs or periorbital edema and showed hyperpla-
sia of lymphatic ear capillaries. This puts forward Pez as a unique
regulator of lymphatic and choanal development. With respect to the
molecular mechanism, Pez was proposed to function in complex with
vascular endothelial growth factor receptor 3, an RTK essential for
lymphangiogenesis [97]. An alternative working scheme results from
studies that implicate polymorphic variants of PTPN14 in themodulation
of the severity of hereditary haemorrhagic telangiectasia (HTT), an
angiogenesis-related vascular dysplasia syndrome [98]. In that study a
functional link of Pez with EphrinB2 or with activin receptor-like kinase
1 was proposed. But perhaps a reﬁnement of the above molecular sce-
narios seems appropriate now that recently Drosophila Pez turned out
a positive regulator of theHippo-Warts signaling cascade,which restricts
ﬂy intestinal stem cell proliferation [99]. Also PTPN14 is an important
player in mammalian Hippo signaling [100–102].2.10. PTPN21
The protein PTPD1, encoded by gene PTPN21, is highly homolo-
gous to Pez but as yet it remains to be determined whether it also
is involved inmammalian Hippo signaling. Gene PTPN21 has been as-
sociated with schizophrenia [103]. Mining of genome wide associa-
tion datasets revealed two non-synonymous sequence variations in
PTPN21 that independently represent signiﬁcant risk alleles for
schizophrenia; p.L385P and p.V936A [103]. How one should envis-
age the contribution of these alterations in size and hydrophobicity
of the involved PTPD1 residues to schizophrenia etiology remains a
future challenge.
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PTPN22 encodes three splice forms of the cytosolic PTP Lyp, also
named PEP, of which the longest isoform of 807 amino acids is the
most abundant and hence best studied. PTPN22 is expressed exclusively
but differentially in haematopoietic cells; Natural Killer cells and neu-
trophils express highest levels while CD4+ T cells and monocytes ex-
press the lowest [104]. A genetic association between type 1 diabetes
and a SNP in the coding region of PTPN22was reported that corresponds
to the so-called R620W amino acid substitution in a polyproline motif
within Lyp that may be involved in SH3 domain-mediated protein in-
teractions [105]. Following this discovery, several reports conﬁrmed
the link to type 1 diabetes for R620W and in fact expanded its clinical
reach tomany other autoimmune diseases, including RA, SLE, myasthe-
nia gravis, Hashimoto thyroiditis, and Addison disease [106,107]. An-
other PTPN22 SNP variant, R263Q, has been associated with psoriasis
risk [108]. Interestingly, a massive genotyping study amongst several
thousand ulcerative colitis and CD patients and healthy controls re-
vealed that the R620W and R263Q polymorphisms in Lyp show differ-
ential association in these patient groups: R263Q predisposes to
ulcerative colitis, whereas R620W was only signiﬁcantly associated
with CD [109]. Likewise, only R620W and not the novel R263Q was
found to inﬂuence systemic sclerosis genetic susceptibility [110]. Final-
ly, both R620W and R263Q variants have been associated with pulmo-
nary tuberculosis [111].
The arginine to tryptophanmutation is autosomal dominant, with in-
creased clinical penetrance in homozygous carriers. Whether R620W
represents a gain- or loss-of-function variant is still debated and it may
even turn out that perhaps both gain- and loss-of-function is at stake.
The ﬁndings in Ptpn22 knockout mice underscore a role for Lyp in nega-
tively regulating SFK-mediated T cell receptor signaling but conversely
the relatively mild loss-of-function phenotype in mice [112] may be
taken as evidence that the human R620W variant represents a
gain-of-function mutant. Mechanistically, thoughts concentrate on the
importance of the polyproline motif in mediating an interaction with
Csk, on direct effects on Lyp catalytic activity and protein stability. The
Lyp–Csk complex is able to synergistically down-regulate the cytoplas-
mic SFKs Lck and Fyn that are instrumental in T cell receptor signal
propagation. Thus, since R620W impairs Lyp–Csk complex formation
[105], hyper-reactivity of T cells against autoantigens may explain
autoinﬂammatory effects. On the other hand, mutant Lyp R620W is cat-
alytically more active [113] which would mean that it could potently
suppress TCR signaling during thymic development, enabling the surviv-
al of autoreactive T cells that would normally be eliminated by negative
selection. Recently, however, it was demonstrated that the R620W Lyp
isoform is degraded more rapidly as compared to the wild type protein
as a result of an increased interaction with and subsequent cleavage by
calpain 1, a calcium-dependent protease [114]. Thus, reduced Lyp levels
may neutralize any gain in speciﬁc activity of the R620W isoform. It will
be insightful to hear about the protein stability of the Lyp R263Q variant
as well in due course.
Intriguingly, the R620Wallele is absent in African and Asian popula-
tions which may reﬂect a trade-off between protection from infections
and susceptibility to autoimmune diseases. The R620W polymorphism
also correlated with the risk of primary resistance to imatinib therapy
in chronic myeloid leukemia patients, suggesting a role for Lyp in
BCR-ABL-related signaling pathways [115]. Potential physiologic sub-
strates of Lyp include TCR zeta, CD3 epsilon, Lck, and ZAP70, among
others [116]. In a recent study [117], the cytosolic adaptor protein
SKAP-HOM has also been identiﬁed as a Lyp substrate, and correspond-
ing X-ray structural data now provide a start to develop therapeutics
that target Lyp and thus may alleviate multiple autoimmune diseases.
It will be crucial, however, to learn what the net result of Lyp-
R620W's decreased protein stability in combination with its increased
enzymatic activity actually is. Importantly, the number of regulatory T
cells in the mouse thymus were found to correlate inversely with Lypprotein levels [118], and this may explain why the R620W allele associ-
ates with autoimmune diseases that have a strong autoantibody com-
ponent (e.g. SLE, RA) and has no or even a protective effect in others
without dominant autoantibodies (e.g. CD).
3. Cys-based classical, receptor-type PTPs
3.1. PTPRA
RPTPα, the product of the PTPRA gene is a receptor-type PTP (RPTP)
that is highly expressed in the developing and adult central nervous sys-
tem in both glial cells and neurons. RPTPα is comprised of tandem intra-
cellular phosphatase domains, but only a short, heavily glycosylated
extracellular portion. RPTPα is the signaling subunit of co-receptor com-
plexes with the cell adhesion molecules CNTN-1 and -6 as well as CHL1
and NCAM [119–122], whereby RPTPα transduces positive signals in
SFK signaling pathways modulating both cell interactions and synaptic
plasticity [123,124]. Polymorphisms in the human PTPRA locus (notably
rs1016753) have been linked to schizophrenia, and post-mortem studies
on humans suffering from schizophrenia show decreased PTPRA tran-
script in the dorsolateral prefrontal cortex [125]. In line with this,
RPTPα knockoutmice exhibit decreased expression ofmultiple genes in-
volved in myelination, and show deﬁcits in spatial learning and de-
creased locomotor activity and anxiety, possibly reﬂecting symptoms
of schizophrenia [125,126]. A candidate effector of these phenotypes is
Fyn, a SFK dephosphorylated and activated by RPTPα. Fyn knockout
mice as well as catalytically inactive Fyn knock-in mice display a severe
myelin deﬁcit [127], and pharmacological inhibition of Fyn decreased
the accumulation of myelin proteins [128].
3.2. PTPRC
The CD45 protein isoforms that are encoded by gene PTPRC already
served as well-established cell surface markers in the hematopoietic
compartment long before the proteins were recognized as PTPs. It re-
quired the ﬁrst phospho-tyrosine phosphatase sequence (of PTP1B) to
disclose that CD45's tandem cytoplasmic domains represent PTP moie-
ties, making CD45 the founding member of the transmembrane PTP
subclass [129,130]. Experiments in mice provided proof that the Ptprc
gene encodes important regulators of immune cell function [131,132]
and protection against viral infection [133]. Ample evidence also links
human PTPRC to immunodeﬁciency disorders and virus susceptibility.
A severe combined immunodeﬁciency (SCID) patient displayed loss of
functional CD45 due to compound heterozygosity; one allele suffered
from a large deletionwhile in the other allele the intron 13 donor splice
site was destroyed by a G-to-A transition [134]. Another SCID patient
was found to carry a small deletion in exon 11 of PTPRC, resulting in a
2-amino-acid-deletion in the extracellular ﬁbronectin type III (FNIII)
domain that prevented expression of the mutant molecule on the cell
surface [135]. Also uniparental disomy for an inactivating mutation in
CD45 has been added to the list of SCID molecular etiologies [136].
A causative role in multiple sclerosis (MS) has been proposed
based on knockout mouse experiments [137] and the ﬁnding that a
SNP within PTPRC was associated with MS in several families [138].
The SNP results in a C-to-G transversion in PTPRC which does not
lead to an amino acid change but rather blocks the alternative splicing
out of exon 4 [139]. However, results of subsequent, much larger
studies rather argue against an association between this PTPRC
77C-G SNP and MS ([140] and references therein). Interestingly, dur-
ing the course of these studies it was noted that the 77C-G allele was
found at a much higher frequency among hepatitis C virus-infected
patients than in healthy controls [141]. Also, 77C-G heterozygotes
are much more frequent among chronic hepatitis C virus carriers
than individuals who resolved hepatitis C virus infection and it is of
note that 77C-G homozygotes were not detected in any of the groups.
Subsequent studies on patient-derived lymphocyte populations and
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mechanism leading to the increased susceptibility to hepatitis C virus
infection among 77C-G heterozygotes [141]. The 77C-G SNP enhances
inclusion of the exon 4-encoded “A” part in CD45 splice isoforms. This
causes an increase in CD45RA+ primed CD8 T cells, in which dephos-
phorylation and activation of Lck is enhanced. Transgenic mice that
mimic this increased CD45RA+ expression also display an altered
CD8+ T cell phenotype, including enhanced proliferative responses
and Lck activation as observed in human peripheral bloodmononuclear
cells. Thus, the 77C-G PTPRC allele results in a more vigorous—and per-
haps non-protective—response and increased disease severity upon
hepatitis C virus infection as compared to the normal allele.
PTPRC is now also added to the expanding list of RA risk genes [142].
The involved SNP (rs10919563) resides within an intron, some 35 kbp
away from the previously discussed C77G SNP that altered PTPRC splic-
ing. Intriguingly, many RA risk SNPs appear located near genes involved
in TNFα signaling and thusmay affect expression regulation of thenear-
by genes. Furthermore, RA risk alleles provedworthy in categorizing RA
patients in clinically meaningful groups, including responsiveness to
anti-TNF therapy. Indeed the PTPRC RA-associated SNP was found re-
peatedly to predict responsiveness to anti-TNF therapy [143,144] and
future work thus should reveal whether it is CD45 or rather a nearby
TNFα pathway component that could explain the disease link.
3.3. PTPRD
Restless legs syndrome (RLS) is an autosomal dominant disorder
that is characterized by nocturnal periods with an irresistible desire to
move the legs that on the long run cause insomnia and chronic sleep
deprivation. Currently, dopaminergic agonists are used for treatment
but, oddly enough, genes involved in dopaminergic transmission are
not associated with the disorder. Instead, the predisposing loci that
thus far have been identiﬁed rather relate to limb development, iron
storage and spinal cord interneuron development [145]. The suscepti-
bility locus on chromosome 9p24–p22 has been subject of debate for
some time [146] but two independent studies now have settled the
issue by demonstrating an association of RLS with the gene PTPRD at
9p24–p23 [147,148]. These studies concentrated on two independent
SNPs that reside in PTPRD introns but that end up in the long 5′
untranslated region of brain-speciﬁc alternative transcripts. PTPRD en-
codes RPTPδ, an RPTP with FNIII and immunoglobulin (Ig) type cell ad-
hesion motifs in its extracellular part. How these PTPRD variants confer
risk of RLS remains as yet enigmatic but, based on ﬁndings in Ptprd
knockout mice [149], it is tempting to postulate that altered stability
of PTPRD transcripts will have bearing on motor neuron axon guidance
and termination during limb development and function. Furthermore,
since the RPTPδ extracellular segment is able to interact with Ig-like do-
mains of interleukin-1-receptor accessory protein-like proteins [150],
which are implicated in cognitive impairment disorders and can induce
dendritic spine formation, PTPδ mutations may also contribute to RLS
by impacting on trans-synaptic signaling events.
Another PTPRD SNP, rs2279776, representing a silent mutation in
the codon for amino acid residue 1418 that resides within the ﬁrst
PTP domain, has now been associated with a higher risk to develop
clear cell renal cell carcinoma [151]. Together with two intronic PTPRD
SNPs, rs2279776 has also been instrumental in associating PTPRD with
pediatric asthma occurrence in Taiwan [152]. The cancer risk allele
resulted in signiﬁcantly lower RPTPδ immuno-reactivity in renal tissue
[153], further implicating RPTPδ as a tumor suppressor protein. Earlier
reports had already pointed to PTPRD loss-of-function mutations in
neuroblastoma, the major childhood cancer arising from precursor
cells of the sympathetic nervous system [154]. In those studies it
appeared that RPTPδ interactswith anddephosphorylates aurora kinase
A (AURKA), an oncogenic protein that is over-expressed in multiple
cancer types. This dephosphorylation results in aurora kinase A degra-
dation and thus eliminates its role in Myc stabilization [154]. Likewise,the molecular mechanism underlying PTPRD's tumor suppressive link
in clear cell renal cell carcinoma may also come down to an aurora
kinase-dependent upregulation of the Myc oncoprotein. A further de-
scription of PTPRD somaticmutations in cancer can be found elsewhere
[6,7].
3.4. PTPRF
PTP LAR, a very close homolog of RPTPδ, is encoded by gene PTPRF; it
also represents an RPTP with extracellularly a collection of Ig-like and
FNIII repeats reminiscent of neural cell adhesion molecules. Ptprf mu-
tant mice show several abnormalities that underscored a role for LAR
in mammary gland development and neuronal development and func-
tion [155–159]. Although PTPRF mutations have been encountered in
somatic pathologies, until recently germline mutations were not
reported. This has now changed with the incidental reporting on a
syndromic amastia patient that presented an inherited reciprocal bal-
anced translocation involving PTPRF [160]. Amastia is the complete ab-
sence of breasts, resulting from complete failure of mammary ridge
development in utero, an extremely rare disorder that displays both au-
tosomal dominant and autosomal recessive modes of inheritance. In
lymphoblastoid cells derived from the affected individual, sharply con-
trasting with ﬁndings in materials from her unaffected relatives that
also carried the interrupted PTPRF allele on the maternal chromosome,
severely reduced PTPRF mRNA levels and absence of LAR protein was
found. This implies that the proband's paternal PTPRF allele harbors
some pathogenic mutation as well but sequence analysis of the tran-
scription unit and promoter region did not yield the desired evidence
but conﬁrmed that the non-affected carrier sisters inherited the other
allele of the deceased father [160]. Further examples of such germline
PTPRF mutations should corroborate these ﬁndings and may provide
the materials to delineate the consequences of reduced LAR levels at
the molecular level that may explain this developmental abnormality.
LAR has been put forward as an important negative modulator of the
insulin signaling pathway [161–163]. However, RNAi-mediated knock-
down of LAR in HEK293 cells did not affect IR and IRS phosphorylation
levels but rather altered downstream Akt/PKB andMAP kinase activities
[164]. Although endogenously LAR is hardly expressed in muscle [165],
its overexpression in muscle tissue of transgenic mice also resulted ex-
clusively in post-receptor effects; IR and IRS-1 phosphorylation appeared
normal whereas IRS-2 phospho-levels and associated PI3-kinase activity
were reduced, causing whole-body insulin resistance [166]. A genetic
variant of the human PTPRF promoter pointed to an associationwith fea-
tures of insulin resistance in two different cohorts, although an effect by
the variant on promoter activity could not be detected [167]. Since insu-
lin resistance is pathogenic for coronary artery disease, particularly
amongst patients with type 2 diabetes, an association with PTPRF gene
variants was tested for this patient group. Both an Italian study [168]
and data from the Wellcome Trust Case Control Consortium [41] reveal
that the minor allele at rs2782641 associates with coronary artery dis-
ease in patientswith type 2 diabetes, likely in a recessivemodel of inher-
itance. The SNP locates in PTPRF intron 3, suggesting that a mechanistic
explanation should be sought at the transcriptional or alternative splic-
ing level.
3.5. PTPRJ
Density-enhanced phosphatase-1 (DEP-1) is a widely expressed
RPTP that is encoded by the PTPRJ gene. Studies in mice provided evi-
dence that the gene is important for vascular development and that it
represents a colon cancer susceptibility locus [169–171]. Although on
the basis of sporadic human tumor samples a potential tumor suppres-
sor activity for DEP-1 could be suggested, no spontaneous tumor devel-
opment was observed in DEP-1 deﬁcient mice [172]. A recent study
revealed that PTPRJ also represents a colorectal cancer susceptibility
locus in human. In two patients with early-onset microsatellite-stable
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mode of inheritance, a large intragenic duplication was identiﬁed that
affected the PTPRJ 5′ end [173]. This micro-duplication resulted in epi-
genetic silencing of the variant PTPRJ allele, in concurrence with copy
number variation-based epimutation mechanisms in a subgroup of
Lynch syndrome patients with hereditary non-polyposis colorectal can-
cer [174]. Additional mutations in the other PTPRJ allele were not ob-
served in one of the patient's tumor material [173], suggestive of an
obligate haploinsufﬁciency scenario as recently put forward for
tumor-related PTEN (phosphatase and tensin homolog) mutations
[175]. In addition, it has also been found that speciﬁc PTPRJ haplotypes
confer different protective effects on breast cancer, papillary thyroid
carcinoma, head andneck squamous cell carcinoma and lung carcinoma
risks [94,176,177]. The molecular basis of the phenomenon has not yet
been explored but it may touch upon DEP-1's ability to interact with
and dephosphorylate cell junction proteins [178]. Finally, SNPs in
PTPRJ that result in amino acid changes that probably affect DEP-1 li-
gand binding capacity, oligomerization and/or phosphatase activity,
were found enriched in patients with heparin-induced thrombocytope-
nia, suggesting a regulatory role for PTPRJ in this thrombosis-related
disease [179]. This would be in line with observations in Ptprj knockout
mice that, next to the SFK-mediated regulatory function of DEP-1 in
B-cells and macrophages [180], also display a bleeding tendency and de-
fective arterial thrombosis [181]. Furthermore, this puts forward that such
PTPRJ polymorphisms also may impact on airway hyperresponsiveness
[182] and bacterial infections [183].
3.6. PTPRN2
Two PTP genes, PTPRN and PTPRN2, encode major autoantigens in
type 1 diabetes mellitus that function in secretory vesicle release as re-
vealed bymouse studies [184]. For a long time it was thought that these
transmembrane PTPs had no catalytic activity themselves and might
perhaps protect phosphotyrosine-containing proteins from being
dephosphorylated by other PTPs through speciﬁc association involving
their impotent catalytic site [185]. However, quite recently evidence
was obtained that phogrin, the protein encoded by gene PTPRN2, actu-
ally does display phosphatase activity but rather towards inositol phos-
pholipids than tyrosine-phosphorylated proteins [186]. The study
suggests that phogrin activity towards PI(4,5)P2 is instrumental in se-
cretory vesicle release, and this may well bear relevance for synaptic
neurotransmitter-dependent processes that are disturbed in neuropa-
thologies. Investigating copy number variations in a large cohort of at-
tention deﬁcit hyperactivity disorder patients led to the assignment of
PTPRN2 as one of many candidate susceptibility genes [187]. A separate
genome-wide linkage scan, to identify genetic factors determining
co-occurrence of cocaine dependence and major depressive episode
with poor treatment outcome and high relapse risk, yielded four prom-
ising candidates including PTPRN2 [188]. Replication of these ﬁndings is
however mandatory before we might start speculating on possible
translational spin-offs.
3.7. PTPRO
PTPRO encodes glomerular epithelial protein 1 (GLEPP1), an RPTP
with multiple extracellular FNIII repeats and a single intracellular cata-
lytic PTP domain. Highest GLEPP1 expression levels are seen in the glo-
merulus of the human kidney [189]. GLEPP1 deﬁciency in mice leads to
aberrant podocyte structures and reduced glomerular ﬁltrative capaci-
ty, indicating that Ptpro plays an important role in pressure/ﬁltration
rate physiology inmice [190]. It should therefore not come as a surprise
that in a recent study a distinct set of idiopathic nephrotic syndromepa-
tients were found to suffer from a homozygous mutation in PTPRO
[191]. Idiopathic nephrotic syndrome is characterized by proteinuria,
hypoalbuminemia and edema, resulting in end-stage kidney disease if
untreated. Reported defects in podocyte structure and function inpatients are reminiscent of the phenotype in Ptpromutant mice. Using
an unbiased approach, via SNP-based genome-wide analysis and homo-
zygosity mapping, a homozygous c.2627+1G>T donor splice-site mu-
tation was identiﬁed in a single family, that results in the splicing out
of exon 16 in GLEPP1 mRNA. Investigation of additional families re-
vealed a second, distinct homozygous c.2745+1G>A donor splice-site
mutation in PTPRO, this time causing skipping of exon 19 and degrada-
tion of the aberrant mRNA via nonsense-mediated decay. Thus, PTPRO
mutations underly autosomal-recessive nephrotic syndrome type 6. In
view of the nature of other glomerular disease genes (including those
encoding nephrin, podocin, phospholipase CE1, α-actinin-4, TRPC6,
formin, Wilms' tumor suppressor protein and laminin B2 [192]) and
the nature of its substrates [193,194] it remains openwhether GLEPP1's
contribution to glomerular function depends on its capacities as a cell
adhesion molecule, its impact on the submembranous cytoskeleton
via intracellular signaling events, or both.
A recent genome-wide study found an association of three PTPRO
intronic SNPs with learning andmemory functions in neurocognitive
disease patients with schizophrenia spectrum disorder or bipolar
disorder [195]. Earlier ﬁndings in Ptpro mutant animals had pointed
to subtle abnormalities in nerve development [196]. This mouse
study entailed tests addressing sensorimotor coordination and sug-
gested both nociception and proprioception to be perturbed. Also
using the in vitro PC12 cell model a major role for GLEPP1 in nerve
growth factor-induced neuronal process outgrowth, through de-
phosphorylation of interacting protein NPCD, has been demonstrat-
ed [197]. Taken together, this urges for substantiation of the human
genetic ﬁndings and for tests on the cognitive abilities of GLEPP1 de-
ﬁcient mice.3.8. PTPRQ
An interesting case is provided by the PTPRQ gene, which also en-
codes anRPTPwithmultiple extracellular FNIII repeats and a single intra-
cellular catalytic PTP domain. PTPRQ favors inositol lipid phosphates
over tyrosine-phosphorylated proteins as substrates [198]. Mutations
in PTPRQ cause autosomal recessive nonsyndromic hearing loss-84
(DFNB84), as was found in two unrelated families with sensorineural
hearing loss and vestibular dysfunction [199,200]. Several years earlier,
studies in mice already predicted this outcome [201]. Mouse Ptprq is
expressed in inner-ear, cochlea and vestibule hair bundles and animals
carrying mutations in gene Ptprq had no shaft connectors in vestibular
hair bundles and misaligned or absent stereocilia. The mutant mice
showed rapid postnatal deterioration in cochlear hair-bundle structure,
progressive loss of affected hair cells and ultimately deafness [201].
Thus the PTPRQ protein is required for the formation of the shaft connec-
tors, normalmaturation and long-term survival of cochlear hair cells. Re-
cent work on the mousemodel also corroborated PTPRQ involvement in
vestibular dysfunction [202].
Human PTPRQ encodes several splice variants that differ in the num-
ber of FNIII repeats in the long extracellular segment of the transmem-
brane PTP. The nonsense mutation that was found in exon 19 of PTPRQ
in DFNB84 patients predicts a truncated proteinwith a reduced number
of FNIII repeats (one to ﬁve, depending on the splice isoform). Also the
Arg-Gly missense mutation that was encountered in exon 19 would af-
fect an FNIII domain; the substitution of a big positively charged residue
by a small uncharged one may well be incompatible with essential in-
teractions mediated by the wild-type protein or, alternatively, the mu-
tant proteinmay not reach the cell surface. Intriguingly, although PTPRQ
is also expressed in other tissues where stereocilia play important roles,
no symptoms other than deafness and vestibular dysfunction were
reported [199,200]. Equally intriguing remains the question whether
PTPRQ functioning solely relies on its extracellular adhesive talents or
whether the catalytic activity towards its phospholipid substrates is rel-
evant as well.
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This gene encodes several receptor-type, internal vesicle-associated,
and cytosolic isoforms, whose expression in cerebellar granular layer
and Purkinje cells is regulated during development [203]. Ptprr knock-
out mice display mild, ataxia-like, locomotive impairment [204].
PTPRR proteins are major regulators of subcellular distribution and cat-
alytic activity of the MAP kinases ERK1/2, ERK5, and p38α, by means of
direct physical interaction and dephosphorylation [205–208]. An
intronic SNP at PTPRR has been associated withmajor depressive disor-
der (MDD) in a Chinese female population. Although the functional out-
come of this PTPRR polymorphism is unknown, the correlation between
low neuronal ERK1/2 activation and mood disorders in humans and in
mouse models [209,210] points to increased PTPRR activity in this dis-
ease. This is in line with the gain-of-function properties attributed to
the PTPRR-related protein, STEP, in the etiology of schizophrenia
([56]; see above). Moreover, the expression of another MAP kinase
inactivator, DUSP1/MKP1 (discussed further on), is increased in the hip-
pocampus of MDD patients, and increased hippocampal DUSP/MKP1
expression in rat and mouse models causes depressive-like behaviors
[211].
3.10. PTPRS
The cell adhesion molecule (CAM)-like RPTPs LAR and RPTPδ that
are implicated in amastia and restless legs syndrome, respectively,
have already been discussed. In humans there is onemore gene that en-
codes such a transmembrane PTP with Ig-like and FNIII type repeats in
the extracellular part; the gene is termed PTPRS and the encoded pro-
tein is RPTPσ. Ptprs mutant mice display a phenotype that betrays im-
portant roles in nervous system and pituitary gland development
[212]. The mice were also found to spontaneously develop mild colitis
that could be readily worsened by providing an experimental challenge
[213]. This led to an investigationwhether SNPs in human PTPRS are as-
sociated with ulcerative colitis. Indeed three intronic SNPs signiﬁcantly
associated with ulcerative colitis and investigation of RPTPσ transcripts
in lymphoblast cell lines that carry the successive SNPs demonstrated
that the risk alleles favor exon 9 skipping, which results in deletion of
the third immunoglobulin-like domain in the extracellular part of
RPTPσ [213]. Thismaywell have bearing for ligand recognition and sub-
strate dephosphorylation and consequently alter barrier defense in
colon tissue. It is noteworthy to mention that adherens junction pro-
teins E-cadherin and β-catenin [213] and the actin cytoskeleton regula-
tor p250GAP [214] are among the RPTPσ substrates. The lattermaywell
explain the inhibitory effect of RPTPσ on nerve outgrowth and regener-
ation [215,216].
Additional RPTPσ substrates are the RTKs Ret and EGFR [217–219].
The insulin receptor may appear an attractive substrate as well but in-
vestigation of the insulin hypersensitivity featured in RPTPσ deﬁcient
mice [220] rather led to the exclusion of RPTPσ as a direct modulator
of insulin receptor signaling in peripheral insulin responsive tissues.
Given RPTPσ's neuroendocrine impact on the regulation of glucose
homeostasis [220] it may still have bearing for diabetes etiology. Poly-
morphisms in the gene were therefore scrutinized for an inﬂuence on
the development of impaired glucose tolerance and type 2 diabetes in
a Swedish cohort [221]. Indeed three SNPs (two in intronic parts of
PTPRS and a synonymous one within exon 33) were found associated
with an increased risk of developing type 2 diabetes. Replication of
these ﬁndings and concomitant allele-speciﬁc PTPRS expression stud-
ies are now required to clarify this further.
3.11. PTPRZ1
PTPRZ1 encodes 4 isoforms, resulting in two transmembrane prod-
ucts, RPTPZ-A and -B, and two soluble, secreted products in the develop-
ing and adult nervous system. RPTPZ-A and -B harbor the classical dualtandem intracellular phosphatase domains, and have extracellular car-
bonic anhydrase and FNIII repeats. The difference lies in the length of
the spacer region between the transmembrane and FNIII repeats;
RPTPZ-A is highlymodiﬁedwith chondroitin sulfate in the spacer region,
whereas RPTPZ-B has a shorter, less-modiﬁed spacer domain. RPTPZ is a
receptor for the cytokine pleitrophin. Soluble RPTPZ (also known as
phosphacan) corresponds to the extracellular portion of RPTPZ-A includ-
ing the modiﬁed CS domain, and is highly N-and O-glycosylated [222].
Ptprz knockoutmicehave been generated andmild changes inmyelin ul-
trastructure, spatial learning defects and altered B cell levels were en-
countered [223–225]. However, subjecting these mice to experimental
autoimmune encephalomyelitis, a well-established mouse model of
MS, revealed a defect in remyelinating capacity in vitro and the process
of remyelination in vivo, which manifested as sustained paralysis associ-
ated with a loss of mature oligodendrocytes in the spinal cord [226].
PTPRZ1 expression is elevated in remyelinating oligodendrocytes at MS
lesions, suggestive of a link between PTPRZ1 and demyelinating disease.
However, current MS susceptibility loci reside on chromosomes 1p36,
5p13, 6q21, and 10p15 and do not include PTPRZ1 on 7q31.3. Further-
more, a recent study on an independently and differently generated
Ptprz knockout mouse strain did not recapitulate the previous experi-
mental autoimmune encephalomyelitis ﬁndings and rather pointed to
a negative regulatory role for RPTPZ isoforms in oligodendrocyte differ-
entiation and remyelination [227]. In yet a third Ptprz knockout mouse
model, and using a distinct experimental demyelination protocol, also
no impairment of in vivo remyelination was detected and instead an im-
portant role in themaintenance of axonal integrity under demyelinating
conditions was disclosed [228]. Either way, RPTPZ proteins remain im-
portant targets of axonal protection in inﬂammatory demyelinating
diseases.
Triggered by the observation in a cell model that PTPRZ1 expression
levels match the degree of cell vacuolation induced by the Helicobacter
pylori virulence determinant protein VacA, Noda and coworkers exam-
ined pathogenicity ofH. pylori, a primary pathogen in benign andmalig-
nant gastroduodenal disease, in Ptprz knockout mice [229]. This
revealed that VacA binds to the PTP and thereby affects phosphorylation
signaling in gastric epithelial cells, which leads to cellular detachment
explaining gastric injury and ulceration. Whether this has bearing for
the human population remains to be investigated.
A cohort study covering 1400 patients diagnosed with schizophrenia
showed association between speciﬁc PTPRZ1 SNPs and schizophrenia in
the British population [230,231]. The schizophrenic patients displayed
a higher expression of RPTPZ-B isoform [232]. However, other work
has failed to demonstrate a similar linkage in the Japanese population
[233]. Recently, it was reported that transgenic mice overexpressing
the human PTPRZ1 locus developed schizophrenic-like changes in behav-
ioral tests [232] and that RPTPZ expression is altered in amygdalas of
schizophrenic patients [234]. Collectively, these studies suggest that
RPTPZ could be involved in schizophrenia. Furthermore, the data are in-
dicative of a role for RPTPZ in the modulation of neuregulin/ERBB4 and
Fyn signaling as the molecular basis of schizophrenia [230]. Many
RPTPZ substrates [235,236] also provide ample ground for speculations
on a possible underlying mechanism.
4. Cys-based DUSP PTPs
4.1. DUSP1
TheDUSP1 gene encodes theMAP kinase phosphatase 1 (MKP1), the
founding member of the MAP kinase phosphatase family of dual-
speciﬁcity phosphatases (DUSPs) [237,238]. MKP1 is a nuclear, induc-
ible, and ubiquitous enzyme that dephosphorylates and inactivates
the MAP kinases JNKs, p38s, and, to a lesser extent, ERK1/2. MKP1
plays an important role as an immune systemmodulator and as amedi-
ator of the anti-inﬂammatory effects of glucocorticoids, as well as a reg-
ulator of cell survival in cancer-related processes [8,239]. Multiple
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increased innate immune responses and inﬂammatory cytokine produc-
tion, and sensitivity to induced arthritis [239,240]. In line with this, a
DUSP1 SNP (rs881152) targeting the gene promoter regionwas associat-
ed with bronchodilator responsiveness of multiethnic asthma patients
treated with inhaled corticosteroids [241]. The preventive role of MKP1
in asthma is further sustained by the ﬁnding that MKP1 expression is
up-regulated by corticosteroids in airway smooth muscle cells, which
mediates the inhibition of TNF-α-induced pro-inﬂammatory IL-6 and
IL-8 secretion [242,243]. Mechanistically, MKP1 up-regulation in airway
smoothmuscle cells seems to bemainly due to increasedmRNA stability
and protein stabilization, suggesting a potential MKP1-mediated thera-
peutic role in asthma for proteasome inhibitors or for inhibitors of
MKP1 mRNA degradation [243,244]. Thus, analysis of MKP1 protein
levels in response to asthma therapies, as well as DUSP1 polymorphism
linkage to other human inﬂammatory diseases, is warranted.
4.2. DUSP6
GeneDUSP6 encodesMKP3, a cytoplasmic dual-speciﬁcity phospha-
tase that dephosphorylates and inactivates ERK1/2 [245]. MKP3 is in-
volved in down-regulation of ERK1/2-mediated signaling during
vertebrate development, and Dusp6 knockout mouse models display
dwarﬁsm-related skeletal abnormalities and cardiac hypercellularity
[246,247]. Human DUSP6 maps to chromosome region 12q22–q23,
one of the reported bipolar disorder loci, and SNPs within the coding
part of DUSP6 (p.Leu114Val and p.Ser144Ala)may contribute to bipolar
disorder in the Korean, but not the Japanese, female population
[248,249]. Functional analysis suggested a dominant enhancing effect
of these mutations on MKP3 phosphatase activity, which would be in
concordance with the hypoactivity of the ERK1/2 pathway detected in
some bipolar disorder patients [250]. Interestingly, residue Leu114
forms part of a Leu-rich sequence in the MKP3 N-terminal regulatory
domain, which is substituted by valine in the two MKP3-related
MKPs, DUSP7/MKPX and DUSP9/MKP4. Further genetic and functional
analysis of theseMKP3 polymorphic variants is necessary to understand
the putative involvement of MKP3 in bipolar disorder.
In two reports a SNP near theDUSP9 gene (rs5945326)was found as-
sociated with type 2 diabetes susceptibility [251,252]. As yet it is unclear
whether DUSP9 expression is affected by the SNP. Therefore we refrain
from a further discussion and only listed this PTP gene in Fig. 1.
4.3. Phosphatase and tensin homolog PTEN
PTEN is undoubtedly as yet the most relevant PTP family member
from a human disease viewpoint. This unique lipid phosphatase counter-
acts the oncogenic phosphatidylinositol 3-kinase by dephosphorylating
the D3 position of phosphatidylinositol 3,4,5-triphosphate [PI(3,4,5)P3].
By virtue of this activity, PTEN is a major tumor suppressor protein
whose function is essential to control cell growth and development and
to prevent tumorigenesis. Accordingly, loss-of-function mutations in the
PTEN gene are found with high incidence in sporadic human cancers
[253,254]. PTEN protein is ubiquitously expressed and shuttles between
cell membrane, cytoplasm and nucleus. The biological activity of
membrane-associated PTEN is the direct dephosphorylation of PI(3,4,5)
P3, although protein phosphatase activity, as well as nuclear functions,
are also ascribed to PTEN [255–260].
Heterozygous germline mutations in the PTEN gene are associated
with hamartomas and hereditary tumor susceptibility syndromes
(including Lhermitte–Duclos disease and Cowden, Bannayan–Riley–
Ruvalcava and proteus syndromes) that have been clustered as
PTEN hamartoma tumor syndromes (PHTS), as well as with autism
spectrum disorders and developmental delay. Mutations are found
all over the PTEN gene, including the promoter and splicing intronic
regions [261–264]. The clinical manifestations of these syndromes
are highly variable, making the molecular analysis of the status ofPTEN gene an important diagnostic tool for patients [265]. In addition,
patients with PHTS also manifest increased risk of obesity, and de-
creased risk of type 2 diabetes due to enhanced insulin sensitivity
[266]. It is likely that patient-speciﬁc PTENmutations render different
PTEN functional properties and distinct clinical manifestations of can-
cer, developmental, and metabolic diseases. For instance, a more
deleterious PI(3,4,5)P3-phosphatase functional pattern has been ob-
served in PTEN mutations found in PHTS than in mutations found in
autism spectrum disorders/developmental delay patients [267].
Homozygous deletion of Pten in mice is embryonic-lethal [268], and
most of tissue-speciﬁc Pten knockout mice display enhanced tumori-
genesis in the targeted tissues [269]. Remarkably, in a conditional
mousemodel of Pten loss in the prostate, acute Pten inactivation triggers
an anti-proliferative, p53-dependent pro-senescence response, which
has been proposed as a candidate pathway for prostate cancer therapy
[270]. Tissue-speciﬁc Pten knockout in thyrocytes displayed goitre and
thyroid adenomas, which is symptomatic of Cowden syndrome [271].
On the other hand, tissue-speciﬁc knockout of Pten in neurons does
not result in neoplasia, but rather in enlargement of brain structures
and abnormal synapse growth and plasticity, accompanied in some
models by behavioral abnormalities. These phenotypes are reminiscent
of one of the PHTS manifestations associated with macrocephaly
(Lhermitte–Duclos disease), or of autism spectrumdisorders and devel-
opmental delay [272–274]. Heterozygous Pten knockout mice recapitu-
late at the molecular and pathological level some of the symptoms
observed in PHTS and autism spectrum disorders/developmental
delay patients [275], and are therefore suitable tools for the validation
and improvement of therapies.
Germline PTENmutations found in patients not only affect PTEN cat-
alytic activity, but also PTEN protein stability and steady-state levels
[276]. Studies in mice with hypomorphic Pten alleles have proved that
a small reduction in PTEN levels favors cancer onset [277], whereas
transgenic mice with systemic overexpression of PTEN are resistant to
cancer and obesity [278,279]. In line with this, different polymorphic
variants of PTEN gene have been negatively or positively correlated
with risk to distinct human cancers, likely by affecting PTEN transcrip-
tion [280–284]. Finally, different PTEN SNPs have been associated in Chi-
nese populations with risk to atherosclerotic cerebral infarction and
coal smoke-linked chronic obstructive pulmonary disease [285,286]. It
is likely that small variations in PTEN expression or function are rele-
vant for the susceptibility of a wide array of human pathologies. Multi-
ple avenues are open to restore or interfere with PTEN biological
activity in the treatment of human disease.
4.4. PTP4A1
PTP4A1 gene encodes PRL-1, the founding member of the phospha-
tase of regenerating liver phosphatases (PRLs; PRL-1, -2, and -3). PRLs
are small DUSPs with oncogenic andmetastatic activities, whichmostly
rely on their catalytic activity, although their physiological substrates
remain uncertain. PRLs are C-terminally prenylated proteins that shut-
tle between the nucleus, the plasma membrane, and internal mem-
branes. In general, PRLs are widely distributed and induced upon
mitogenic stimulation, and are over-expressed in malignant human
cancers [287–289]. PRL-1 promoting-activity on cell migration and in-
vasion has been related with a positive regulation of the Src/p130Cas,
RhoA/Rock, and ERK1/2 pathways [290,291]. Also, a role for PRL-1 in
promoting cell cycle progression, likely by up-regulation of CDK2 and
Cyclin A, and down-regulation of p21 levels, has been proposed [292].
A genome-wide association analysis found a signiﬁcant correla-
tion of several SNPs at gene PTP4A1with risk for alcohol dependence,
most of which were found to be functional by mRNA expression data
from HapMap database [293]. This is concordant with genome-wide
expression analysis showing signiﬁcant increase in PTP4A1 mRNA ex-
pression upon ethanol consumption in mice [294]. Further molecular
analysis is required to validate PTP4A1 as a genetic trait of alcohol
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tion of PRL-1 on this dependence and its relation with PRLs oncogenic
activity.
4.5. Myotubularin-related proteins
Mytotubularin and myotubularin-related proteins (MTMR) consti-
tute a group of active and inactive DUSPs that contain one PTP domain
and several protein- or lipid-interaction regulatory domains. Active
MTMRs dephosphorylate the D3 phosphate from phosphatidylinositol
3-phosphate and phosphatidylinositol 3,5-bisphosphate, generating
phosphatidylinositol and phosphatidylinositol 5-phosphate, respec-
tively. Since these lipids play crucial roles in membrane functionality,
including membrane remodeling, endosome and lysosome trafﬁcking,
and autophagy, MTMRs play an essential role in human physiology
and disease [295–298]. In addition, myotubularins have been involved
in the control of cell survival signaling through Akt/PKB and caspase
pathways [299,300]. Functional defects in MTM1 and MTMR14 are
associated with centronuclear myopathies, whereas mutations in
MTMR2 and MTMR13 are causative of demyelinating neuropathies.
Other myotubularin-related genes represent risk alleles for various dis-
eases, as will be described further on.
4.6. MTM1
The myotubularin gene MTM1 is mutated in X-linked recessive
myotubular (centronuclear) myopathy (XLMTM) [301–304] a severe
neonatal disorder characterized by muscle weakness and hypotonia,
as a result of abnormalities in the maturation and/or regeneration of
skeletal muscle ﬁbers. Skeletal muscle ﬁbers from XLMTM patients dis-
play centrally located nuclei that resemble fetal myotubes, and the ma-
jority of affected males die early after birth [305].Mtm1 knockout mice
recapitulate the human disease well, and display amyotrophy of skele-
talmuscleﬁbers as a result of defects in skeletalmuscle structuralmain-
tenance, which leads to death 6–14 weeks after birth. Skeletal muscle
contraction inMtm1 knockoutmice is defective due to T-tubule disorga-
nization [306,307]. SomeMTM1mutations, such as themissensemuta-
tion rendering the Arg69Cys substitution, are associated with a mild
XLMTM phenotype in patients, likely as the consequence of reduced
MTM1 function or protein levels. A mouse p.Arg69Cys knock-in model
also showed a mild phenotype in mice, illustrating that mutation-
related phenotypic variability in XLMTM patients can be mimicked in
mouse models [303,308]. A dog model of MTM1 functional deﬁciency
also reproduces human XLMTM disease [309] and MTM1 knock-down
in zebraﬁsh also showed T-tubule disorganization, with defects inmus-
cle excitation-contraction coupling [310]. MTM1 binds to desmin, a
muscle-speciﬁc proteinmutated in familial cardiac and skeletal myopa-
thies, and disruption of MTM1-desmin complex results in an abnormal
intermediate ﬁlament network in skeletal muscle, independently of
MTM1 catalytic activity [311]. Whether other MTM-related proteins
regulate intermediate ﬁlament architecture deserves further studies.
In line with the possibility of MTM1 phosphatase-independent func-
tions, viral gene transfer of catalytically inactive MTM1 ameliorated
XLMTM-like phenotype inMtm1 knockout mice [312]. Thus, MTM1 in-
volvement in human myopathies goes beyond its catalytic activity.
4.7. MTMR14
MTMR14 (Jumpy, MPI) is mutated in patients with sporadic
centronuclear myopathy, a muscular disease with milder manifestations
than XLMTM. Pathogenic mutations compromise PTP activity and its ca-
pacity to negatively regulate autophagy [313–315]. Mtmr14 knockout
mice displayed muscle weakness and fatigue, likely as a consequence of
Ca2+ leakage from the sarcoplasmic reticulum. In addition, these mice
displayed a decline in muscle function that is reminiscent of aging
sarcopenia, in correlation with defective Ca2+ homeostasis [316,317].Mtmr14 knockdown zebraﬁsh embryos also showed increased
autopaghy and myoﬁber hypotrophy, as well as impaired muscle ex-
citation–contraction and compromised motor function. Remarkably,
an additive effect in the impairment of motor function was observed
in zebraﬁsh upon knockdown of both Mtm1 and Mtmr14 expres-
sion [318], suggesting compensatory effects in the functions mediat-
ed by these enzymes.
4.8. MTMR2 and SBF2
Two other MTMRs, MTMR2 and MTMR13 (encoded by gene SBF2),
are involved in the pathogenesis of the Charcot-Marie-Tooth (CMT) de-
myelinating neuropathies, which also manifest with muscle weakness
and atrophy in the extremities [319,320]. In analogy with MTM1-
desmin interaction in skeletal muscle, MTMR2 associates physically in
neurons with the neuroﬁlament light chain protein (NF-L) that is mu-
tated in axonal and intermediate CMT neuropathies [321]. MTMR2 is
an active phosphatase, butMTMR13 is inactive as an enzyme and rather
directly regulates the activity of MTMR2 by heterodimerization [322].
Mutations in MTMR2 or SBF2 genes are causative of CMT4B1 and
CMT4B2 disease, respectively, which are symptomatically indistin-
guishable [323–325], and Mtmr2 and Mtmr13 knockout mice display a
similar CMT4B-like phenotype [326–329]. An intronic SNP at SBF2
gene (rs10734652) associated with stature variation in Caucasian and
Chinese populations [330].
4.9. MTMR3, MTMR7 and MTMR9
Several SNPs that associate with human diseases have been detected
in some other MTM-related genes. These include SNPs at MTMR3
(rs17728461 and rs36600, susceptibility to lung and gastric cancer;
rs2412973, susceptibility to childhood-onset inﬂammatory bowel disease
[331–333]), MTMR7 (linked to variant Creutzfeld-Jakob neurodegenera-
tive disease; intronic variant rs4921542 [334], andMTMR9 (susceptibility
to metabolic syndrome and obesity; rs2293855 [335,336]). Follow-up
studies, to replicate these ﬁndings and to unravel the involved molecular
etiology, are eagerly awaited.
4.10. EPM2A
Laforin is a ubiquitously expressed DUSP that localizes in the cyto-
plasm and in the nucleus, binds to glycogen, and forms amolecular com-
plex with malin, an E3 ubiquitin ligase. It has been proposed that the
complex laforin-malin regulates the ubiquitination and proteasome-
mediated degradation of proteins involved in glycogen metabolism,
and in the protein-degradation response to endoplasmic reticulum stress
[337–339]. Loss-of-function mutations in the genes encoding laforin
(EPM2A) or malin (NLHRC1) account for more than 90% of the cases of
Lafora disease (LD), an autosomal recessive neurodegenerative disorder
that presentswith progressivemyoclonus epilepsy andneurological dys-
functions, and ends with death about 10 years after onset [340–343]. A
pathological characteristic of LD is the presence of Lafora bodies, insolu-
ble, poorly branched, and heavily phosphorylated glucose polymers that
accumulate primarily in neurons from the central nervous system. Po-
tential substrates of laforin include phosphorylated glycogen, glycogen
metabolism-related proteins (such asGSK3-β) and Tauprotein, although
it is believed that the physiologic and pathologic role of laforin may go
beyond its phosphatase enzymatic activity [344–346].
Laforin is required for the proper formation of autophagosomes,
and it has been proposed as a positive regulator of autophagy
[347,348]. Although contradicting ﬁndings have been reported on
glucose metabolism and insulin sensitivity from laforin knockout
mice [349,350], it seems that glycogen metabolism and degradation
of macromolecules and/or organelles seem to be under the control
of laforin activity. Laforin has also been proposed to suppress tumor
growth in immune-compromised mice, to negatively regulate cell
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[351–353]. However, thus far no genetic alterations in the EMP2A
gene have been reported to be associatedwith cancer. Laforin knockout
mice recapitulate several LD symptoms, including laforin disease-like
neuronal and behavioral disorders, and the presence of Lafora bodies,
particularly abundant in heart and brain, which increased with age
[345,354,355]. In the brain, these mice displayed hyperphosphorylated
Tau protein and neuroﬁbrillary tangles, aswell as prominent changes in
expression of genes involved in post-translational modiﬁcation of pro-
teins and transcriptional regulation [344]. In addition, increased endo-
plasmic reticulum stress and impaired proteasomal function was
found in the liver, but not in the brain, of laforin knockout mice [356].
LD shows a high allelic heterogeneity, and a large number of distinct
mutations have been found in LD-affected families, that include mis-
sense, non-sense, insertion, and deletionmutations [357]. The function-
al consequences of these mutations are variable, including total or
partial lack of expression of laforin, altered subcellular location, defects
in laforin phosphatase activity, or decreased binding to glycogen, malin
or regulatory proteins [340]. This likely contributes to the phenotype
heterogeneity observed in LD patients, although variability in the age
at onset of the disease has also been documented in patients harboring
the same mutation [358], suggesting the involvement of genetic modi-
ﬁers [340]. Remarkably, alternative splicing of laforin gene generates
phosphatase inactive isoforms that may act as dominant negative
interactors of the active isoforms [359,360], and these interactions can
also be affected by LD mutations. In addition, laforin variants exist
(e.g. p.Ala46Pro) that do not co-segregate with the LD phenotype, cor-
roborating involvement of other genes in LD [361].
5. Asp-based PTPs
The Drosophila Eyes absent (Eya) gene constitutes the prototype for
class IV PTPs, and encodes a nuclear protein that is essential for eye de-
velopment. Operating both as transcription factor and as enzyme it is
required for organ and tissue development in a variety of organisms, in-
cluding mammals [362]. EYA is a constituent of a transcription factor
complex involving, in vertebrates, the SIX homeodomain proteins and
the DACH transcriptional regulator. The phosphatase activity of EYA is
instrumental for switching between transcriptional repression and acti-
vation states of the complex, and mutations that impair EYA catalytic
activity sufﬁce to obstruct eye development [362]. EYA proteins operate
as phospho-tyrosine- and phospho-threonine-directed phosphatases;
the N-terminal half carries phospho-threonine activity and the C-
terminal haloacid dehalogenase (HAD) domain contains the PTP activi-
ty [363]. Of interest, the EYA phosphatases display pro-angiogenic prop-
erties and are overexpressed in several human cancers, and EYA
tyrosine phosphatase activity promotes breast cancer cell invasion,
transformation and metastasis, although the EYA substrates related
with these functions remain unknown [364–367]. EYA proteins have
also been proposed to regulate DNA damage repair by targeting the
DNA damage-related histone H2AX [368,369]. Identiﬁcation of EYA
physiological substrates remains an important issue, especially now
that both human developmental defects and cancer have been attribut-
ed to impaired or dysregulated EYA activity.
5.1. EYA1
In human there are four EYA genes, and loss of phosphatase activity
mutations in EYA1 are associated with branchio-oto-renal syndrome
[370]. Branchio-oto-renal syndrome is an autosomal dominant disorder
characterized by hearing loss, structural ear defects, branchial ﬁstulas
or cysts, and renal abnormalities [371]. A spectrum of over eighty differ-
ent EYA1 mutations have been reported but a clear-cut correlation be-
tween the severity of the phenotype and the involved EYA1 mutation
or domain could not be extracted [372]. EYA1mutations are also associ-
ated with oto-facio-cervical syndrome, which shares clinical featureswith branchio-oto-renal syndrome but ismuchmore severe due to addi-
tional features like sloping shoulders, developmental delay and short
stature [373]. Large deletions involving the EYA1 gene region were ob-
served in oto-facio-cervical cases, underscoring that oto-facio-cervical
and branchio-oto-renal syndrome are allelic and suggesting that other
deleted genes centromeric to EYA1 are responsible for the additional clin-
ical features. Knock-down of the Eya1 ortholog interactors Sipl1 and
Rbck1 in zebraﬁsh caused a branchio-oto-renal syndrome-like pheno-
type, supporting the role of Eya1 in the involved regulatory networks
[374]. An extensive study towards risk alleles for vesico-ureteral reﬂux,
a consequence of ureteric budding defects, yielded a trend for EYA1
SNPs but so far signiﬁcancewas not reached [375]. Given EYA1's potency
to control epithelial cell fate—involving PKC, Notch and Shh pathways—it
nevertheless presents an appealing candidate.
5.2. EYA4
Mutations in the fourth EYA-encoding gene in human, EYA4, have
been identiﬁed in patients that present autosomal dominant non-
syndromic sensorineural deafness type 10, illustrating that EYA4 is
not only important during early embryogenesis but is essential for
continued functioning of the organ of Corti throughout adult life as
well [376–378]. Eya4 knockout mice phenocopy the disease and in
addition put forward EYA4 as a candidate predisposition gene for
human otitis media susceptibility [379]. In some kindreds sensori-
neural hearing loss is followed by dilated cardiomyopathy and
heart failure [380] due to a large deletion in EYA4 that results in a se-
verely truncated EYA4 protein [381]. The picture emerges that
nonsyndromic deafness is caused by EYA4 proteins with a deleted
HAD domain but an intact N-terminal part, whereas syndromic hear-
ing loss with dilated cardiomyopathy results from truncations in-
volving the N-terminal domain of the protein as well [381,382].
Two additional genetic ﬁndings are worthwhile mentioning. First, a
genome-wide strategy to identify genetic loci determining successful
response to anti-TNF treatment in RA showed the strongest effect for
an intronic SNP within gene EYA4 [383] and further testing will be re-
quired to clarify this proposed relationship. Finally, a case has been de-
scribed in which EYA4was part of a large (10 Mbp) deleted region that
caused a mild, middle interhemispheric variant of holoprosencephaly
(HPE, a congenital malformation of the developing human forebrain
in which the cerebral hemispheres are not properly separated) [384].
Intriguingly, EYA4 was found to interact with the nuclear transcription
factor SIX3, which is encoded by a known HPE disease gene, and to
serve as co-activator [384]. Thus, EYA4 haploinsufﬁciency may contrib-
ute to HPE through compromising SIX3 transcriptional activity.
6. Perspective
After two decades of molecular research on PTPs, the ﬁeld has
achieved major goals in the understanding of the biological properties
of this family of enzymes, including their evolutionary history, reaction
mechanisms, versatility of regulation, substrate speciﬁcity properties,
and structure-function relationships [5]. Moreover, experimental evi-
dence has been obtained on the active involvement of PTPs as drivers
of major human pathologies, including a panoply of hereditary diseases
and syndromes (Fig. 4). As for other enzymes, PTPs represent potential
targets for pharmacological inhibition, and especially PTP1B has been
extensively studied in this respect in view of its negative role in insulin
signaling and, more recently, its positive role in cell growth and trans-
formation [385]. Direct enzymatic inhibition of PTPs whose expression
positively correlates with hereditary diseases, such as PTPN1 or
PTPN5, may represent an effective palliative therapy. This, however,
would require a new generation of PTP inhibitors with high bioavail-
ability and speciﬁcity before a clinical validation of this direct PTP inhib-
itory therapeutic approach in the treatment of hereditary diseases can
take place. Alternatively, the activation of physiological PTP-speciﬁc
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same effect, and research in this area needs to be reinforced. Also, de-
creasing speciﬁc PTP protein levels by stimulating targeted protein deg-
radation could be a suitable therapeutic approach, as was proposed for
the degradation of CDC25A in breast cancer [386].
Most PTPs described in this review demonstrate loss-of-function
mutations in diseases,making restoration of intrinsic PTP enzymatic ac-
tivity a potential point of intervention (Fig. 2).Mutations that affect pro-
tein stability may permit restoration of normal activity levels by
modulators. In most of the cases, however, intrinsic PTP activity is irre-
versibly damaged and such an approach would be ineffective. Gene
therapy or alternative activation of related PTPs deserves exploration
in such situations. In addition, directly ﬁne-tuning the activity of the
PTP's relevant downstream targets provides an appealing option to
compensate for the loss of PTP activity. For both options it is mandatory
to obtain in-depth knowledge on the physiologic regulation of PTPs
themselves and on the nature of their key substrates.
Several of the current PTP-linked pathologies likely involve mild al-
terations in the mRNA or protein steady-state expression levels of the
PTP, as witnessed by the associated SNPs at non-coding regions and
the afore-mentioned amino-acid substitutions affecting protein stabili-
ty. Although this has to be experimentally corroborated for many cases,
therapeutic approaches can be envisioned that restore the physiological
levels of the affected PTPs. This applies particularly for the cases where
reduction in PTP levels underlie the disease, such as reduced PTEN ex-
pression in some PHTS patients or increased PTP1B expression in
some patients with insulin resistance. Perhaps in these cases RNAmod-
ulation therapy could provide the necessarymeans to interferewith the
speciﬁc gene-transcription regulatory networks that govern PTP ex-
pression. Such interventions may range from the application of anti-
sense oligonucleotides that alter disease gene expression or splicing,
as currently exploited in type 2 diabetes [387] or Duchenne muscular
dystrophy clinical trials [388], to themanipulation ofmiRNA-based con-
trol over PTP gene expression. Antisense oligonucleotides targeting
PTP1B improve insulin sensitivity in rodents and monkeys [31,32],
and microinjection of miRNA-210 (that targets PTP1B transcripts) led
to improved cardiac function in amousemodel ofmyocardial infarction
[389]. In this light it should be mentioned that studies on miRNA bind-
ing sites in PTP transcripts have barely taken place. A noteworthy ex-
ception is the case of PTEN, where competing endogenous RNAs
coming from its pseudogene help to sequester miRNAs that otherwise
would downregulate this crucial PTP [390].
Apart from the long-term aim of opening therapeutic possibilities,
the genetic analysis of pathological PTP gene variants directly has bear-
ing for clinical diagnostics of rare or heterogeneous diseases and genetic
counseling. In some cases the PTPmutation can be related to the pheno-
type (Table 1). However, in most cases, especially for SNPs outside the
PTP coding regions, the genetic variants could not yet be transferred in
a genotype-phenotype correlation relevant for the patients. Especially
for PTPs that both suffer disease-related gain-of-function and loss-of-
function alterations, such as SHP2 or PTPN22, this information is essen-
tial to enable proper diagnosis, counseling and treatment.
In summary, the above documents the growing importance of
PTPs in human hereditary disease, not only as active players in dis-
ease progression and development but also as potential targets for
therapeutic interventions. At the same time it illustrates that much
more research is required before molecular approaches to restore
PTP function linked to human diseases can be offered to the clinic.
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